1. A novel paradigm links mitochondrial dysfunction with muscle stem cell impairment in sepsis
- Author
-
Franck Verdonk, Fabrice Chrétien, Miria Ricchetti, Clément Crochemore, Pierre Rocheteau, Laurent Chatre, Cellules Souches et Développement / Stem Cells and Development, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Service d'Anesthésie réanimation [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Histopathologie humaine et Modèles animaux, Institut Pasteur [Paris], TRial Group for Global Evaluation and Research in SEPsis (TRIGGERSEP), Centre Hospitalier Sainte Anne [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes, Sorbonne Paris Cité, This work was supported by Institut Pasteur and CNRS funding (UMR 3525 and UMR 3738)., Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Institut Pasteur [Paris] (IP)
- Subjects
0301 basic medicine ,MESH: Inflammation ,Satellite Cells, Skeletal Muscle ,[SDV]Life Sciences [q-bio] ,Inflammation ,Mitochondrion ,Biology ,Mesenchymal Stem Cell Transplantation ,DNA, Mitochondrial ,Sepsis ,03 medical and health sciences ,Muscle stem cells ,medicine ,Animals ,Humans ,MESH: Animals ,MESH: Mesenchymal Stem Cell Transplantation ,Muscle Strength ,Myopathy ,Molecular Biology ,MESH: Sepsis ,MESH: Humans ,MESH: Muscle Strength ,Mesenchymal stem cell ,MESH: DNA, Mitochondrial ,MESH: Satellite Cells, Skeletal Muscle ,Muscle weakness ,Skeletal muscle ,MESH: Mitochondria, Muscle ,medicine.disease ,Mitochondrial DNA ,Mitochondria, Muscle ,3. Good health ,Mitochondria ,030104 developmental biology ,medicine.anatomical_structure ,MESH: Mesenchymal Stem Cells ,Immunology ,Molecular Medicine ,Mesenchymal stem cells ,medicine.symptom ,Stem cell - Abstract
International audience; Sepsis is an acute systemic inflammatory response of the body to microbial infection and a life threatening condition associated with multiple organ failure. Survivors may display long-term disability with muscle weakness that remains poorly understood. Recent data suggest that long-term myopathy in sepsis survivors is due to failure of skeletal muscle stem cells (satellite cells) to regenerate the muscle. Satellite cells impairment in the acute phase of sepsis is linked to unusual mitochondrial dysfunctions, characterized by a dramatic reduction of the mitochondrial mass and hyperactivity of residual organelles. Survivors maintain the impairment of satellite cells, including alterations of the mitochondrial DNA (mtDNA), in the long-term. This condition can be rescued by treatment with mesenchymal stem cells (MSCs) that restore mtDNA alterations and mitochondrial function in satellite cells, and in fine their regenerative potential. Injection of MSCs in turn increases the force of isolated muscle fibers and of the whole animal, and improves the survival rate. These effects occur in the context of reduced inflammation markers that also raised during sepsis. Targeting muscle stem cells mitochondria, in a context of reduced inflammation, may represent a valuable strategy to reduce morbidity and long-term impairment of the muscle upon sepsis.
- Published
- 2017
- Full Text
- View/download PDF